Effects of Antidepressants in Patients With Functional Esophageal Disorders or Gastroesophageal Reflux Disease: ASystematic Review

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 2, 2015, Pages 251-259.e1

  Weijenborg, Pim W ^a   de Schepper, Heiko S ^b   Smout, André J P M ^a   Bredenoord, Albert J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Esophagus; Functional gastrointestinal disorders; Pain modulation; Visceral nociception

Indexed keywords

ANTIDEPRESSANT AGENT; IMIPRAMINE; PAROXETINE; SERTRALINE; TRAZODONE; VENLAFAXINE;

ARTICLE; DRUG EFFICACY; DYSPHAGIA; EMBASE; ESOPHAGUS DISEASE; ESOPHAGUS PAIN; FUNCTIONAL DISEASE; FUNCTIONAL ESOPHAGEAL DISORDER; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; MEDLINE; META ANALYSIS; NOCICEPTION; PAIN THRESHOLD; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; THORAX PAIN; ESOPHAGEAL DISEASES; GASTROINTESTINAL DISEASES; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; ESOPHAGEAL DISEASES; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASES; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84927653095     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.06.025     Document Type: Review

References (45)

1. Galmiche J.P., Clouse R.E., Bálint A., et al. Functional esophageal disorders. Gastroenterology 2006, 130:1459-1465.
2. Martinez S.D., Malagon I.B., Garewal H.S., et al. Non-erosive reflux disease (NERD)-acid reflux and symptom patterns. Aliment Pharmacol Ther 2003, 17:537-545.
3. Zerbib F., Belhocine K., Simon M., et al. Clinical, but not oesophageal pH-impedance, profiles predict response to proton pump inhibitors in gastro-oesophageal reflux disease. Gut 2012, 61:501-506.
4. Savarino E., Pohl D., Zentilin P., et al. Functional heartburn has more in common with functional dyspepsia than with non-erosive reflux disease. Gut 2009, 58:1185-1191.
5. Eslick G.D., Jones M.P., Talley N.J. Non-cardiac chest pain: prevalence, risk factors, impact and consulting-a population-based study. Aliment Pharmacol Ther 2003, 17:1115-1124.
6. Moloy P.J., Charter R. The globus symptom. Incidence, therapeutic response, and age and sex relationships. Arch Otolaryngol 1982, 108:740-744.
7. Drossman D.A., Li Z., Andruzzi E., et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993, 38:1569-1580.
8. Knowles C.H., Aziz Q. Basic and clinical aspects of gastrointestinal pain. Pain 2009, 141:191-209.
9. Knowles C.H., Aziz Q. Visceral hypersensitivity in non-erosive reflux disease. Gut 2008, 57:674-683.
10. Savarino E., Zentilin P., Savarino V. NERD: an umbrella term including heterogeneous subpopulations. Nat Rev Gastroenterol Hepatol 2013, 10:371-380.
11. Ford A.C., Talley N.J., Schoenfeld P.S., et al. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009, 58:367-378.
12. Saarto T., Wiffen P.J. Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2007, 4:CD005454.
13. Jadad A.R., Moore R.A., Carroll D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12.
14. Gorelick A.B., Koshy S.S., Hooper F.G., et al. Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humans. Am J Physiol 1998, 275:G460-G466.
15. Peghini P.L., Katz P.O., Castell D.O. Imipramine decreases oesophageal pain perception in human male volunteers. Gut 1998, 42:807-813.
16. Broekaert D., Fischler B., Sifrim D., et al. Influence of citalopram, a selective serotonin reuptake inhibitor, on oesophageal hypersensitivity: a double-blind, placebo-controlled study. Aliment Pharmacol Ther 2006, 23:365-370.
17. Clouse R.E., Lustman P.J., Eckert T.C., et al. Low-dose trazodone for symptomatic patients with esophageal contraction abnormalities. A double-blind, placebo-controlled trial. Gastroenterology 1987, 92:1027-1036.
18. Cannon R.O., Quyyumi A.A., Mincemoyer R., et al. Imipramine in patients with chest pain despite normal coronary angiograms. NEngl J Med 1994, 330:1411-1417.
19. Varia I., Logue E., O'connor C., et al. Randomized trial of sertraline in patients with unexplained chest pain of noncardiac origin. Am Heart J 2000, 140:367-372.
20. Doraiswamy P.M., Varia I., Hellegers C., et al. Arandomized controlled trial of paroxetine for noncardiac chest pain. Psychopharmacol Bull 2006, 39:15-24.
21. Spinhoven P., Van der Does A.J., Van Dijk E., et al. Heart-focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive-behavioral therapy and paroxetine. JPsychosom Res 2010, 69:227-235.
22. Lee H., Kim J.H., Min B.-H., et al. Efficacy of venlafaxine for symptomatic relief in young adult patients with functional chest pain: a randomized, double-blind, placebo-controlled, crossover trial. Am J Gastroenterol 2010, 105:1504-1512.
23. Cox I.D., Hann C.M., Kaski J.C. Low dose imipramine improves chest pain but not quality of life in patients with angina and normal coronary angiograms. Eur Heart J 1998, 19:250-254.
24. Keefe F.J., Shelby R.A., Somers T.J., et al. Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study. Pain 2011, 152:730-741.
25. Nguyen T.M.T., Eslick G.D. Systematic review: the treatment of noncardiac chest pain with antidepressants. Aliment Pharmacol Ther 2012, 35:493-500.
26. Viazis N., Keyoglou A., Kanellopoulos A.K., et al. Selective serotonin reuptake inhibitors for the treatment of hypersensitive esophagus: a randomized, double-blind, placebo-controlled study. Am J Gastroenterol 2012, 107:1662-1667.
27. Hershcovici T., Jha L.K., Gadam R., et al. Comparison of therapeutic strategies for patients with refractory gastroesophageal reflux disease (GERD) - a randomized, double blind, placebo-controlled trial. Gastroenterology 2011, 140. S-579.
28. Forcelini C.M., Tomiozzo J.C., Farré R., et al. Effect of nortriptyline on brain responses to painful esophageal acid infusion in patients with non-erosive reflux disease. Neurogastroenterol Motil 2014, 26:187-195.
29. Ostovaneh M.R., Saeidi B., Hajifathalian K., et al. Comparing omeprazole with fluoxetine for treatment of patients with heartburn and normal endoscopy who failed once daily proton pump inhibitors: double-blind placebo-controlled trial. Neurogastroenterol Motil 2014, 26:670-678.
30. Broeders J.A., Draaisma W.A., Bredenoord A.J., et al. Oesophageal acid hypersensitivity is not a contraindication to Nissen fundoplication. Br J Surg 2009, 96:1023-1030.
31. You L.-Q., Liu J., Jia L., et al. Effect of low-dose amitriptyline on globus pharyngeus and its side effects. World J Gastroenterol 2013, 19:7455-7460.
32. Brown S.R., Schwartz J.M., Summergrad P., et al. Globus hystericus syndrome responsive to antidepressants. Am J Psychiatry 1986, 143:917-918.
33. Cybulska E.M. Globus hystericus-a somatic symptom of depression? The role of electroconvulsive therapy and antidepressants. Psychosom Med 1997, 59:67-69.
34. Anderson I.M. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. JAffect Disord 2000, 58:19-36.
35. Gorard D.A., Libby G.W., Farthing M.J. Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome. Aliment Pharmacol Ther 1994, 8:159-166.
36. Rohof W.O., Bennink R.J., de Ruigh A.A., et al. Effect of azithromycin on acid reflux, hiatus hernia and proximal acid pocket in the postprandial period. Gut 2012, 61:1670-1677.
37. Tobey N.A., Carson J.L., Alkiek R.A., et al. Dilated intercellular spaces: a morphological feature of acid reflux-damaged human esophageal epithelium. Gastroenterology 1996, 111:1200-1205.
38. Kessing B.F., Bredenoord A.J., Weijenborg P.W., et al. Esophageal acid exposure decreases intraluminal baseline impedance levels. Am J Gastroenterol 2011, 106:2093-2097.
39. Woodland P., Al-Zinaty M., Yazaki E., et al. Invivo evaluation of acid-induced changes in oesophageal mucosa integrity and sensitivity in non-erosive reflux disease. Gut 2013, 62:1256-1261.
40. Dworkin R.H., O'Connor A.B., Backonja M., et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007, 132:237-251.
41. Yang M., Li Z., Chen D., et al. Quantitative assessment and characterization of visceral hyperalgesia evoked by esophageal balloon distention and acid perfusion in patients with functional heartburn, nonerosive reflux disease, and erosive esophagitis. Clin J Pain 2010, 26:326-331.
42. Bhat Y.M., Bielefeldt K. Capsaicin receptor (TRPV1) and non-erosive reflux disease. Eur J Gastroenterol Hepatol 2006, 18:263-270.
43. Guarino M.P.L., Cheng L., Ma J., et al. Increased TRPV1 gene expression in esophageal mucosa of patients with non-erosive and erosive reflux disease. Neurogastroenterol Motil 2010, 22:746-751. e219.
44. Krarup A.L., Ny L., Astrand M., et al. Randomised clinical trial: the efficacy of a transient receptor potential vanilloid 1 antagonist AZD1386 in human oesophageal pain. Aliment Pharmacol Ther 2011, 33:1113-1122.
45. Krarup A.L., Ny L., Gunnarsson J., et al. Randomized clinical trial: inhibition of the TRPV1 system in patients with nonerosive gastroesophageal reflux disease and a partial response to PPI treatment is not associated with analgesia to esophageal experimental pain. Scand J Gastroenterol 2013, 48:274-284.